Cargando…

Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice

The therapeutic sc"enario of metastatic renal cell cancer (mRCC) has noticeably increased, ranging from the most studied molecular target therapies to those most recently introduced, up to immune checkpoint inhibitors (ICIs). The most recent clinical trials with an ICI-based combination of mole...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roberto, Michela, Botticelli, Andrea, Panebianco, Martina, Aschelter, Anna Maria, Gelibter, Alain, Ciccarese, Chiara, Minelli, Mauro, Nuti, Marianna, Santini, Daniele, Laghi, Andrea, Tomao, Silverio, Marchetti, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100507/ https://www.ncbi.nlm.nih.gov/pubmed/33968762 http://dx.doi.org/10.3389/fonc.2021.657639

Ejemplares similares

The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management
por: Roberto, Michela, et al.
Publicado: (2023)

The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets
por: Roberto, Michela, et al.
Publicado: (2023)

Immune effects of CDK4/6 inhibitors in patients with HR(+)/HER2(−) metastatic breast cancer: Relief from immunosuppression is associated with clinical response
por: Scirocchi, Fabio, et al.
Publicado: (2022)

The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study
por: Roberto, Michela, et al.
Publicado: (2022)

Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2020)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

Clinical Outcome of Third-Line Pazopanib in a Patient with Metastatic Renal Cell Carcinoma
por: Roberto, Michela, et al.
Publicado: (2015)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma
por: Bassanelli, Maria, et al.
Publicado: (2021)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
por: Botticelli, Andrea, et al.
Publicado: (2022)

Early results of PRO-EPI: PROspective multicenter observational study on elective pelvic nodes irradiation in patients with intermediate/high/very high-risk non-metastatic prostate cancer submitted to radical, adjuvant, or salvage radiotherapy with or without concomitant androgen deprivation therapy
por: Guerini, Andrea Emanuele, et al.
Publicado: (2022)

Breast cancer metastatic to the pituitary gland: a case report
por: Spinelli, Gian Paolo, et al.
Publicado: (2012)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Circulating CD137(+) T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer
por: Zizzari, Ilaria Grazia, et al.
Publicado: (2022)

Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario
por: Trevisani, Francesco, et al.
Publicado: (2022)

Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis
por: Arrivi, Giulia, et al.
Publicado: (2022)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2022)

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer
por: Tomao, Silverio, et al.
Publicado: (2006)

Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
por: Botticelli, Andrea, et al.
Publicado: (2018)

Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience
por: Valeriani, Maurizio, et al.
Publicado: (2019)

Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach
por: Botticelli, Andrea, et al.
Publicado: (2023)

Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment
por: Gianni, Caterina, et al.
Publicado: (2022)

Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study
por: Rossi, Ernesto, et al.
Publicado: (2022)

Genomic and epigenomic alterations in prostate cancer
por: Aschelter, Anna M., et al.
Publicado: (2012)

CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy
por: Sacchetti, Benedetto, et al.
Publicado: (2019)

An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report)
por: Panebianco, Martina, et al.
Publicado: (2021)

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Treatment and outcome of metastatic parathyroid carcinoma: A systematic review and pooled analysis of published cases
por: Alberti, Andrea, et al.
Publicado: (2022)

The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study
por: Krasniqi, Eriseld, et al.
Publicado: (2022)

Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
por: Botticelli, Andrea, et al.
Publicado: (2020)

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2020)

Level IV tumor thrombus in non-metastatic renal cell cancer? No, thanks. Level II is better. Lessons learned from a case report
por: Galosi, Andrea Benedetto, et al.
Publicado: (2021)

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study
por: Di Lisa, Francesca Sofia, et al.
Publicado: (2023)

The role of opioids in cancer response to immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2021)

Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
por: Papa, Anselmo, et al.
Publicado: (2016)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
por: Ralli, Massimo, et al.
Publicado: (2020)

Retrospective Evaluation of the Effectiveness of a Synthetic Glue and a Fibrin-Based Sealant for the Prevention of Seroma Following Axillary Dissection in Breast Cancer Patients
por: De Luca, Alessandro, et al.
Publicado: (2020)

Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study
por: Ceccarelli, Fulvia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pucv5splgn5d63bormsa661o8s